Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-30 @ 12:25 AM
Study NCT ID:
NCT07457203
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-09
First Post:
2026-02-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study on the Drug Interaction Between Buagafuran and Voriconazole
Sponsor:
Beijing Union Pharmaceutical Factory Ltd
Organization:
Study Overview
Official Title:
Clinical Study on the Drug Interaction Between Buagafuran Capsules and Voriconazole Tablets in Chinese Adult Healthy Participants
Status:
NOT_YET_RECRUITING
Status Verified Date:
2026-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a non-randomized, open label trial aimed at evaluating the drug interaction between Buagafuran capsules and voriconazole tablets in Chinese adult healthy participants.The research period is 7 days in total.
Detailed Description:
This study is a single center, non-randomized, open label trial aimed at evaluating the drug interaction between Buagafuran capsules and voriconazole tablets in Chinese adult healthy participants.
The number of participants in this study is 18, and it is planned to enroll 4-6 participants for the trial first. After completing the day7 safety check, the remaining participants will enter the group.
Participants are required to take a single dose of 30 mg Buagafuran on the morning of day1 and day5. Voriconazole tablets (400 mg BID) orally on day3, and voriconazole tablets (200 mg BID) orally from day4 to day6.
The number of participants in this study is 18, and it is planned to enroll 4-6 participants for the trial first. After completing the day7 safety check, the remaining participants will enter the group.
Participants are required to take a single dose of 30 mg Buagafuran on the morning of day1 and day5. Voriconazole tablets (400 mg BID) orally on day3, and voriconazole tablets (200 mg BID) orally from day4 to day6.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: